Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 20;29(11):2066–2074. doi: 10.1158/1078-0432.CCR-22-2765

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 1. Forest plot of OS in the tTMB-high versus tTMB-low subgroups by tTMB cutoff with durvalumab monotherapy (A) or with durvalumab plus tremelimumab (B) in HAWK/CONDOR. HRs were calculated as tTMB-high versus -low for each treatment group. HR, hazard ratio; OS, overall survival; tTMB, tissue tumor mutational burden. — Forest plot of OS in the tTMB-high versus tTMB-low subgroups by tTMB cutoff with durvalumab monotherapy (A) or with durvalumab plus tremelimumab (B) in HAWK/CONDOR. HRs were calculated as tTMB-high versus -low for each treatment group. HR, hazard ratio; OS, overall survival; tTMB, tissue tumor mutational burden.